IDH2

Biomarkers

IDH2 is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
IDH2 p.R140Q	Somatic Variant	1	1
IDH2 p.R140L	Somatic Variant	1	1
IDH2 p.R140G	Somatic Variant	1	1
IDH2 p.R140W	Somatic Variant	1	1
IDH2 p.R172K	Somatic Variant	3	5
IDH2 p.R172M	Somatic Variant	3	5
IDH2 p.R172G	Somatic Variant	3	5
IDH2 p.R172S	Somatic Variant	3	5
IDH2 p.R172W	Somatic Variant	3	5

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	IDH2 p.R140Q	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R140L	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R140G	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R140W	Acute Myeloid Leukemia	Enasidenib
FDA (1)	IDH2 p.R172K	Acute Myeloid Leukemia	Enasidenib
EMA (1) FDA (1)	IDH2 p.R172K	Astrocytoma	Vorasidenib
EMA (1) FDA (1)	IDH2 p.R172K	Oligodendroglioma	Vorasidenib
FDA (1)	IDH2 p.R172M	Acute Myeloid Leukemia	Enasidenib
EMA (1) FDA (1)	IDH2 p.R172M	Astrocytoma	Vorasidenib
EMA (1) FDA (1)	IDH2 p.R172M	Oligodendroglioma	Vorasidenib
FDA (1)	IDH2 p.R172G	Acute Myeloid Leukemia	Enasidenib
EMA (1) FDA (1)	IDH2 p.R172G	Astrocytoma	Vorasidenib
EMA (1) FDA (1)	IDH2 p.R172G	Oligodendroglioma	Vorasidenib
FDA (1)	IDH2 p.R172S	Acute Myeloid Leukemia	Enasidenib
EMA (1) FDA (1)	IDH2 p.R172S	Astrocytoma	Vorasidenib
EMA (1) FDA (1)	IDH2 p.R172S	Oligodendroglioma	Vorasidenib
FDA (1)	IDH2 p.R172W	Acute Myeloid Leukemia	Enasidenib
EMA (1) FDA (1)	IDH2 p.R172W	Astrocytoma	Vorasidenib
EMA (1) FDA (1)	IDH2 p.R172W	Oligodendroglioma	Vorasidenib